Pregnenolone for the Treatment of Alcohol Use Disorder

NCT05781009 PHASE2 RECRUITING

This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).

Details

Lead sponsor	Yale University
Phase	PHASE2
Status	RECRUITING
Enrolment	150
Start date	Mon Jan 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 31 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Alcohol Use Disorder

Interventions

• Pregnenolone
• Placebo

Countries

United States